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Abstract
Background: Health-related productivity loss is an important, yet overlooked, component of the economic burden
of disease in asthma patients of a working age. We aimed at evaluating the effect of comorbidities on productivity
loss among adult asthma patients.
Methods: In a random sample of employed adults with asthma, we measured comorbidities using a validated
self-administered comorbidity questionnaire (SCQ), as well as productivity loss, including absenteeism and
presenteeism, using validated instruments. Productivity loss was measured in 2010 Canadian dollars ($). We used a
two-part regression model to estimate the adjusted difference of productivity loss across levels of comorbidity,
controlling for potential confounding variables.
Results: 284 adults with the mean age of 47.8 (SD 11.8) were included (68 % women). The mean SCQ score was 2.
47 (SD 2.97, range 0–15) and the average productivity loss was $317.5 per week (SD $858.8). One-unit increase in
the SCQ score was associated with 14 % (95 % CI 1.02–1.28) increase in the odds of reporting productivity loss, and
9.0 % (95 % CI 1.01–1.18) increase in productivity loss among those reported any loss of productivity. A person with
a SCQ score of 15 had almost $1000 per week more productivity loss than a patient with a SCQ of zero.
Conclusions: Our study deepens the evidence-base on the burden of asthma, by demonstrating that comorbidities
substantially decrease productivity in working asthma patients. Asthma management strategies must be cognizant
of the role of comorbidities to properly incorporate the effect of comorbidity and productivity loss in estimating
the benefit of disease management strategies.
Keywords: Asthma, Comorbidities, Productivity loss, Presenteeism, Absenteeism
Abbreviations: BC, British columbia; CAD, Canadian dollars; EBA study, Economic burden of asthma study;
ED, Emergency department; GINA, Global initiative for asthma; NOC, National occupation classification; OR, Odds
ratio; PDC, Proportion of days covered (by any asthma controller medication); RR, Relative rate; SCQ, Self-
administered comorbidity questionnaire; SD, Standard deviation; VOLP, Valuation of Lost Productivity; WPAI, Work
productivity and activity impairment
Background
With increasing life expectancy there has been an
increase in the prevalence of many chronic diseases and
the co-existence of multiple diseases [1–3]. Clinically,
comorbidities are relevant given their potential effect on
the index disease in terms of diagnosis, prognosis, and
management [4]. Also, comorbid conditions increase the
need for medication, risk of adverse effects and drug inter-
actions, and reduce adherence to treatments, quality of life
and functional status [1, 5, 6]. Patients with multiple
comorbidities tend to use more medical services and
impose a greater burden on the health-care system [2, 6].
Asthma is associated with several comorbidities;
however, the prevalence varies across studies [5–8]. In a
study from the United States, 26 and 10 % of asthma
patients had at least one or ≥3 comorbidities, respect-
ively [7]. In a study from Germany, 26 % of asthma
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patients had at least one other comorbidity while 17 %
had 2 or more [9]. In a Canadian study, almost 60 % of
asthma patients had at least one comorbidity [6], while
in another study 12.5 % of adult asthma patients
reported having three or more comorbidities, increasing
to 20 % for adults 55 years and older [5, 6].
It has been well demonstrated that comorbidities are
associated with poor outcomes in asthma patients [10].
Asthma patients with comorbidities experience more
asthma exacerbations [6, 11–13] and there is a significant
relationship between asthma control and the presence of
comorbidities [4, 14, 15]. The reason behind this fact is
unclear. It could be because the patient places a higher
priority on other health conditions, which influences the
adherence to asthma treatment. Also the nature of comor-
bidities like depression may cause the patient to pay less
attention to their general health status and care less [7]. In
a Canadian province, British Columbia (BC), 25 % of
asthma patients have depression [5]. Also, comobidities
could directly and causally affect the severity of asthma or
its responsiveness to treatment; examples include rhinitis
and gastroesophageal reflux disease [16].
It has been demonstrated that indirect costs of asthma
accounted for the greater proportion of costs of asthma
than direct costs, however most of the studies unnoticed
this amount [16]. Also despite the documented burden
of comorbidities in asthma, their effect on productivity
loss has been overlooked in the past. One reason behind
this status is that asthma patients are a relatively young
population and are assumed to be free of comorbidities
[15]. The general increase in longevity and the increase
in the retirement age will inevitably result in more and
more working asthma subjects. The aim of the present
study was to evaluate the effect of comorbidities on
productivity loss in a population-based sample of adult
asthma patients.
Methods
Study design and participants
This study is based on data from the Economic Burden
of Asthma (EBA), a 1-year prospective cohort study with
the specific aim of estimating the economic and human-
istic burden of asthma (University of British Columbia
Human Ethics Board H10-01542). In the EBA study, 618
patients with self-reported physician diagnosis asthma
who were aged 1–85 were recruited by random digit dial-
ing and followed up for a year. The study’s catchment
areas were Vancouver and Central Okanagan census areas,
the latter being in the interior of the BC Province with a
large fraction of the population residing in rural areas.
The details of this study have been described previously
[17, 18] and the inclusion criteria of the present study are
the same as the main EBA, having at least one encounter
with healthcare system because of asthma in the past 5
years and having no plan to move out of the region in the
next year, except it was restricted to adult (≥19 years old)
patients who were employed at the baseline visit.
Variables
Comorbidity
A comorbidity score was calculated based on the Self-
administered Comorbidity Questionnaire (SCQ) admin-
istered in the last visit [19]. The recall period of the
questionnaire is 12 months and thus we assumed co-
morbidity score was constant across the study period
[19]. The SCQ score not only considers the number of
the comorbidities but also their severity. Each included
comorbid condition can get a maximum of three points
based on the presence of disease, whether receiving
treatment, and any functional limitation due to the con-
dition. This questionnaire has been validated and has a
moderately strong correlation with the widely popular
Charlson comorbidity index [19]. The Charlson index is
mainly designed for hospitalized patients and its evalu-
ation needs access to medical records [19]. On the other
hand, the SCQ is designed and validated for the out-
patient settings by relying on patient self report as the
principle source of information [19]. The original SCQ
includes 13 common comorbidities, but in this study the
questions related to pulmonary disorders were excluded
(given that all patients had asthma), leaving the ques-
tionnaire with a maximum of 36 scores, three points for
each of the 12 questions. The included comorbidities
were heart disease, hypertension, diabetes mellitus, ulcer
or stomach disease, kidney disease, liver disease, anemia
or other blood disease, cancer, depression, osteoarthritis
or degenerative arthritis, back pain, and rheumatoid
arthritis.
Productivity loss
Productivity loss was measured at baseline by two
validated questionnaires: the Work Productivity and
Activity Impairment (WPAI) [20], and the Valuation of
Lost Productivity (VOLP) [21]. The WPAI records
patients’ absenteeism (missing work due to health condi-
tions) and presenteeism (attending work but not being
fully functional) in the last 7 days by asking about the
hours they missed from work because of sick days or the
times they went in late or left early due to health status
and times they were not functional with limited accom-
plishment and unable to concentrate on their tasks due
to the health status respectively [20]. The VOLP
questionnaire collects information about the work
environment such as time sensitivity of the job, team
work, and availability of replacement, to calculate a
coefficient that measures the contribution of individual
to the work place (a coefficient of X indicates that each
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hour of a person’s absence is equivalent of X hours of
work loss) [21, 22].
The monetary value of productivity loss per week was
the product of three terms: amount of work time (hours)
lost, the VOLP coefficient, and the hourly wage of the
individual. Job titles were matched to the National Occu-
pation Classification (NOC) codes [23] to estimate the
hourly wage based on sex and age for each NOC from
Statistics Canada for year 2010 [17]. The reported weekly
costs are therefore in 2010 Canadian dollars (CAD).
Confounders
Socio-demographic data collected at the baseline visit
were included in the statistical models as potential
confounders (factors that can affect both comorbid level
and productivity but are not on the causal pathway).
They included: sex, age, household income levels (low v.
high at cut-off of CAD$60,000 per year), education (low
v. high at cut-off of 4-year college/university degree),
type of residence (urban v. rural), place of birth (Canada
v. abroad), drug insurance (having no insurance, being
partially insured, or being fully insured), and the propor-
tion of days covered (PDC) by any asthma controller
medication in past 12 months as an indicator of
adherence (cut-off values <50 %, 50–80 %, ≥80 %).
The main analysis did not adjust for asthma control as
it cannot be a confounder; rather, it is potentially being
on the causal pathway (that is, part of the impact of
comorbidity on productivity might be due to the comor-
bid conditions’ affecting the likelihood of achieving
asthma control. It is also very unlikely for the current
asthma control status to have an effect on comorbidities
(thus being confounding factor). But a sensitivity analysis
was performed to assess the effect of adjusting for control
status on the outcomes. We defined control status based
on Global Initiative for Asthma (GINA) 2012 definition,
which included the presence of symptoms and impair-
ment in lung function (all measured at baseline visit).
Statistical analysis
All analyses were performed using Stata (version 14;
StataCorp, College Station, TX, USA). Two-tailed p-values
at 0.05 were considered statistically significant. Descriptive
analysis was performed on the baseline variables. We
reported the hours and costs of both components of prod-
uctivity loss (absenteeism and presenteeism), as well as
total productivity loss across different levels of SCQ score.
As the productivity loss data were zero-inflated, we
used two-part models for statistical inference [24]. The
first part was a logistic component and the second part
was a generalized linear model with logarithmic link
function and gamma distribution. The first part gener-
ates odds ratio (OR) associating covariates with any loss
of productivity, and the second component produces
relative rate (RR) associating covariates with the magni-
tude of productivity loss among those with any loss of
productivity. For both components the dependent variable
was the monetary value of productivity loss and the inde-
pendent variables were the SCQ score and other covari-
ates as previously mentioned. As there were missing
values among some of the covariates, multiple imputa-
tions were first performed, creating 5 imputed datasets
without missing variables; results of separate analyses on
the imputed datasets were combined. To estimate the
marginal effect of SCQ on productivity loss (that is, the
weekly loss of productivity associated with any level of
SCQ score), the OR and RR from the two components
were combined, and p-values and confidence intervals
were estimated using bootstrapping (500 times) as
described elsewhere [25]. The procedure was conducted
separately with absenteeism, presenteeism, and total prod-
uctivity loss as the dependent variable.
Results
Figure 1 shows the flowchart of sample selection. The
final sample consisted of 284 individuals whose baseline
characteristics are shown in Table 1. The sample was
68 % female with a mean age of 47.8 ± 11.8 with gener-
ally high levels of education and household income.
Most of the subjects (63 %) had at least one comorbid
condition and the overall SCQ score was 2.47 ± 2.97,
with a minimum of 0 and a maximum of 15. Only 48 %
of patients reported any productivity loss, with 36 % of
them reporting absenteeism and 64 % reporting present-
eeism. Mean weekly hours and costs of productivity loss
were 16 ± 17.6 h and $317.49 ± $858.83 respectively.
Fig. 1 Flow chart of study population
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Unadjusted analysis
Table 2 shows the results of unadjusted analysis. The
hours of absenteeism increased from 1.26 to 7.14 h as
the SCQ increased from 0 to 15, and for presenteeism it
rose from 3.97 to 12.59 h. The costs of absenteeism
increased from $50/week for SCQ of 0 to almost $300/
week for SCQ of 15, while the corresponding values for
presenteeism was $140/week and $734/week. The same
increases were seen for the total productivity loss, from
$190/per week to $1036/per week.
Adjusted analysis
The results of two-part regression model are demon-
strated in Table 3. In the logistic part of the analysis,
SCQ was significantly associated with higher odds of
reporting absenteeism, presenteeism and total productiv-
ity loss. However, in the second part of the regression,
among patients with productivity loss, SCQ was only
significantly associated with the total productivity loss
(RR = 1.09, CI = 1.01-1.18, P = 0.02) and not presentee-
ism or absenteeism separately. The other covariates were
not significantly associated with productivity loss in
either parts of the model.
Marginal effect of comorbidity on productivity loss
The marginal effect of each level of SCQ score on total
productivity loss is demonstrated in Fig. 2. In patients
without any comorbidity, the productivity loss was
$205 week. Total productivity loss was $1685 higher
with a SCQ score of 15 in comparison to a SCQ score of
zero. The margins were significant at all the levels,
except SCQ score of 15 (P-value = 0.06). For Absentee-
ism, the costs were from $61.87/week (SD = 23.07) for
SCQ score of 0 to $612.61/week (SD = 498.06) for
those with the score of 15, and for presenteeism they
were from $160.92/week (SD = 32.57) to $877.33/week
(SD = 473) for the SCQ scores of 0 and 15, respect-
ively. However the incremental costs for the SCQ
score of ≥10 for absenteeism and SCQ score of 15
for presenteeism were not significant.
Table 1 Characteristics of study sample
Study population = 284











Place of birth (%)
Canada 207 (72.9)








Asthma medication adherence (%)
PDCb < 50 % 171 (60.2)
50 %≤ PDC < 80 % 31 (11)
PDC≥ 80 % 81 (28.5)
Missing 1 (0.3)
Asthma control level (%)
Controlled 55 (19.4)
Partially Controlled 113 (39.8)
Uncontrolled 115 (40.5)
Missing 1 (0.3)
Productivity Loss (%) 136 (48)
Absenteeism (%) 49 (17)
Presenteeism (%) 127 (45)
Hours of overall productivity loss,
mean ± SD
16 ± 17.6
Costsc of overall productivity loss,
mean ± SD
317.49$ ± 858.83$
Overall SCQd comorbidities score,
mean ± SD
2.47 ± 2.97
Heart disease (%) 15 (5.3)
Hypertension (%) 35 (12.3)
Diabetes (%) 9 (3.2)
Ulcer or Stomach Disease (%) 37 (13)
Kidney disease (%) 3 (1.1)
Table 1 Characteristics of study sample (Continued)
Liver disease (%) 2 (0.7)
Anemia or other blood disease (%) 21 (7.4)
Cancer (%) 6 (2.1)
Depression (%) 40 (14.1)
Osteoarthritis, degenerative arthritis (%) 62 (21.8)
Back pain (%) 99 (34.9)
Rheumatoid arthritis (%) 2 (0.7)
aStandard deviation
bproportions of days covered
c2010 Canadian dollars
dself-administered comorbidity questionnaire
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Sensitivity analysis
Sensitivity analysis revealed that OR for reporting
productivity loss and adjusted ratio for productivity loss
among those reporting it did not change by adding
control status in the model. However, the adjusted RR in
the second part was no longer significant. Adding
control status to the model did not have a significant
impact on the estimates of the marginal loss of product-
ivity (Appendix).
Discussion
In this study, we have demonstrated that as the SCQ score,
a validated quantitative measure of the burden of comor-
bidity, increased, the hours of absenteeism and presentee-
ism increased significantly to almost 20 h per week. This
caused almost $1685/week higher productivity loss in
patients with a score of 15, the maximum score observed
in our sample, in comparison to those with a zero score.
The average SCQ score in the sample was 2.47 (SD 2.97).
Table 2 Unadjusted regression analysis












0 1.26 50.35 3.97 140.20 5.22 190.18
(0.54–1.98) (19.88–80.81) (2.73–5.22) (65.27–215-13) (3.49–6.96) (97.22–283.14)
1 1.65 66.91 4.55 179.81 6.20 246.60
(0.99–2.32) (40.19–93.63) (3.48–5.62) (118.75–240.87) (4.70–7.70) (169.16–324.03)
2 2.04 83.47 5.12 219.41 7.17 303.01
(1.22–2.87) (49.80–117.14) (4.00–6.25) (145.85–292.98) (5.52–8.83) (208.30–397.72)
3 2.44 100.03 5.70 259.02 8.15 359.43
(1.33–3.54) (53.27–146.79) (4.31–7.08) (155.75–362.28) (6.04–10.26) (226.90–491.95)
4 2.83 116.59 6.27 298.62 9.13 415.84
(1.38–4.27) (54.35–178.83) (4.51–8.03) (159.03–438.21) (6.41–11.85) (237.59–594.10)
5 3.22 133.15 6.84 338.22 10.10 472.26
(1.41–5.03) (54.45–211.86) (4.65–9.04) (159.70–516.76) (6.70–13.50) (245.10–699.42)
6 3.61 149.71 7.42 377.83 11.08 528.67
(1.43–5.79) (54.06–245-36) (4.76–10.08) (159.12–596.53) (6.96–15.20) (251.09–806.25)
7 4.00 166.27 7.99 417.43 12.05 585.09
(1.44–6.56) (53.42–279.13) (4.85–11.13) (157.90–676.97) (7.19–16.91) (256.28–913.90)
8 4.39 182.83 8.57 457.04 13.03 641.50
(1.45–7.34) (52.61–313.06) (4.94–12.20) (156.28–757.79) (7.42–18.64) (260.97–1022.03)
9 4.79 199.39 9.14 496.64 14.01 697.92
(1.45–8.12) (51.70–347.09) (5.01–13.27) (154.41–838.87) (7.63–20.38) (265.36–1130.48)
10 5.18 215.96 9.72 536.24 14.98 754.33
(1.46–8.90) (50.72–381.19) (5.09–14.34) (152.38–920.11) (7.84–22.12) (269.53–1239.14)
11 5.57 232.52 10.29 575.85 15.96 810.75
(1.46–9.68) (49.69–415.35) (5.16–15.42) (150.23–1001.47) (8.05–23.86) (273.56–1347.94)
12 5.96 249.08 10.86 615.45 16.93 867.17
(1.46–10.46) (48.62–449.54) (5.23–16.50) (147.98–1082.92) (8.26–25.61) (277.48–1456.86)
13 6.35 265.64 11.44 655.06 17.91 923.58
(1.46–11.25) (47.52–483.75) (5.29–17.58) (145.68–1164.43) (8.46–27.36) (281.31–1565.85)
14 6.74 282.20 12.01 694.66 18.88 979.99
(1.45–12.03) (46.41–517.99) (5.36–18.67) (143.32–1246) (8.66–29.11) (285.08–1674.91)
15 7.14 298.76 12.59 734.26 19.86 1036.41
(1.45–12.82) (45.27–552.25) (5.42–19.75) (140.93–1327.60) (8.86–30.86) (288.80–1784.03)
All the p-values <0.05
a2010 CAD
bThe sum of the costs of absenteeism and presenteeism are not exactly equal to the costs of total productivity loss, because the exact distribution of error terms
around each component is inevitably different in regression models
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Table 3 Results of the adjusted regression analysis of productivity loss on SCQa score
Absenteeism Presenteeism Total Productivity
Loss
Female v. male Adjusted OR for reporting productivity loss 1.72 1.08 0.99
(0.53–2.57) (0.61–2.35) (0.56–1.76)
(P = 0.7) (P = 0.77) (P = 0.99)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.42 0.88 0.79
(0.15–1.18) (0.52–2.18) (0.46–1.37)
(P = 0.1) (P = 0.63) (P = 0.41)
Age (per 1 year increase) Adjusted OR for reporting productivity loss 0.98 0.98 0.98
(0.95–1.01) (0.96–1.04) (0.96–1.01)
(P = 0.31) P = (0.13) (P = 0.23)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.98 0.99 0.98
(0.94–1.03) (0.96–1.04) (0.96–1.01)
(P = 0.5) (P = 0.49) (P = 0.18)
High v. urban education Adjusted OR for reporting productivity loss 1.16 0.68 0.52
(0.41–3.27) (0.34–2.84) (0.25–1.1)
(P = 0.73) (P = 0.27) (P = 0.09)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.92 1.50 1.44
(0.29–2.96) (0.84–2.40) (0.76–2.72)
(P = 0.9) (P = 0.17) (P = 0.26)
Rural residence Adjusted OR for reporting productivity loss 0.47 0.38 0.41
(0.13–1.75) (0.11–6.17) (0.13–1.35)
(P = 0.26) (P = 0.11) (P = 0.14)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.99 0.42 0.44
(0.05–20.88) (0.21–2.88) (0.16–1.15)
(P = 0.99) (P = 0.1) (P = 0.1)
Foreign Born v.
Canadian-born
Adjusted OR for reporting productivity loss 0.95 1.00 1.21
(0.41–2.19)) (0.56–2.42) (0.67–2.17)
(P = 0.92) (P = 0.99) (P = 0.53)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.41 0.84 0.72
(0.12–1.39) (0.52–2.08) (0.43–1.19)
(P = 0.16) (P = 0.5) (P = 0.2)
PDCb Level
(Reference: PDC < 50 %)
50–80 % Adjusted OR for reporting productivity loss 2.75 1.27 1.34
(0.98–7.73) (0.54–3.66) (0.58–3.10)
(P = 0.07) (P = 0.59) (P = 0.49)
Adjusted ratio of productivity loss among
those who reported productivity loss
1.49 2.50 2.72
(0.33–6.64) (0.70–6.77) (0.91–8.10)
(P = 0.6) (P = 0.15) (P = 0.07)
>80 % Adjusted OR for reporting productivity loss 1.11 0.86 0.97
(0.48–2.59) (0.47–2.50) (0.52–1.80)
(P = 0.8) (P = 0.6) (P = 0.93)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.95 1.13 1.13
(0.40–2.29) (0.69–2.08) (0.68–1.86)
(P = 0.91) (P = 0.62) (P = 0.64)
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At this level, productivity loss was almost 1.5 times higher
than in individuals without any comorbidity (SCQ= 0). In
the full two-part regression, SCQ increased the odds of
reporting productivity loss, absenteeism and or presentee-
ism by 14–17 %. In addition, among those with prod-
uctivity loss, one-unit increase in SCQ increased
productivity loss by 9 %. Overall, our results demon-
strate the substantial effect of comorbidity on prod-
uctivity loss in patients with asthma.
Previous studies assessing the impact of comorbidities
on asthma patients mostly focused on direct costs or
health services use [7, 12, 15, 26]. For example, they
have demonstrated that the rate of hospitalization due
to asthma and Emergency Department (ED) visits in
asthma patients increased in the presence of comorbidi-
ties [7, 12, 15, 26]. It has also been shown that the pres-
ence of some comorbidities increase the risk of mortality
[10, 26]. The relationship between comorbidities and
asthma exacerbations has also been demonstrated [6]. A
study conducted in Finland showed that the presence of
one and more than two comorbidities increased the risk
of work disability with hazard ratios of 2.2 and 4.5,
respectively [27]. In that study, work disability was
defined as long-term sickness absence (≥90 days) and
receiving a disability pension. Results of current study are
inline with our previous study that demonstrated the
presence of comorbid psychological conditions in asthma
patients will increase productivity loss significantly [28].
To the best of our knowledge, there is no other study
assessing the general impact of comorbidities on product-
ivity loss in asthma patients including both absenteeism
and presenteeism and transforming the productivity loss
into its monetary value. The use of validated instruments
enabled us to transform productivity loss time to its
monetary value, incorporating the impact of the affected
individual on team productivity, and the use of a robust
statistical method enabled us to properly handle statistical
issues around zero-inflated and skewed costs data.
Besides these strengths, our study has several limitations
worth mentioning. First, the final sample size (284) might
have underpowered the results and our sample were mostly
highly educated with high income, which could manifest
Table 3 Results of the adjusted regression analysis of productivity loss on SCQa score (Continued)
Drug Insurance (Reference: full insurance)
Partial Adjusted OR for reporting productivity loss 1.36 1.03 1.11
(0.41–4.49) (0.45–3.44) (0.47–2.63)
(P = 0.59) (P = 0.94) (P = 0.8)
Adjusted ratio of productivity loss among
those who reported productivity loss
0.84 0.60 0.73
(0.20–3.53) (0.24–3.99) (0.30–1.80)
(P = 0.82) (P = 0.17) (P = 0.5)
None Adjusted OR for reporting productivity loss 0.82 0.91 0.86
(0.20–3.43) (0.36–4.07) (0.33–2.25)
(P = 0.82) (P = 0.86) (P = 0.76)
Adjusted ratio of productivity loss among
those who reported productivity loss
1.09 0.66 0.76
(0.16–7.33) (0.24–4.58) (0.28–2.11)
(P = 0.93) (P = 0.42) (P = 0.61)
High v. low income Adjusted OR for reporting productivity loss 0.84 0.87 0.88
(0.37–1.88) (0.48–2.47) (0.47–1.66)
(P = 0.54) (P = 0.66) (P = 0.7)
Adjusted ratio of productivity loss among
those who reported productivity loss
1.47 1.27 1.27
(0.55–3.93) (0.74–2.25) (0.69–2.32)
(P = 0.44) (P = 0.38) (P = 0.44)
SCQ (per 1 unit increase) Adjusted OR for reporting productivity loss 1.17 1.14 1.14
(1.04–1.32) (1.03–1.17) (1.02–1.28)
(P = 0.01) (P = 0.01) (P = 0.01)
Adjusted ratio of productivity loss among
those who reported productivity loss
1.04 1.05 1.09
(0.90–1.21) (0.98–1.11) (1.01–1.18)
(P = 0.56) (P = 0.14) (P = 0.02)
aSelf-administered comorbidity questionnaire
bproportion of days covered by medication
Ehteshami-Afshar et al. Respiratory Research  (2016) 17:106 Page 7 of 9
the healthy volunteer bias. Second, our sample only
included employed asthma patients. None of the partici-
pants in the original study reported being unemployed
because of asthma. As such, we could not incorporate the
loss of productivity for asthma patients who lose their job
due to the asthma-related or comorbidity-related impair-
ment. Third, self-reported physician diagnosis of asthma
and self-reported comorbidities and productivity loss might
reduce the accuracy of the data we used. Fourth, the per-
centage of patients with higher scores of SCQ was limited
such that the results for the patients with SCQ scores of
≥10 should be interpreted cautiously. Ultimately, the aspect
of the burden of a disease that is the most relevant for
clinical practice and policy-making is the component that
can be prevented by disease management. Having docu-
mented a significant association between comorbidity and
productivity loss, the research agenda should move forward
to studying specific comorbid conditions as well as the im-
pact of treatment on preventing such loss of productivity.
Conclusions
Taking the limitations into account, our study has
highlighted the important associations of comorbidities with
productivity loss in working asthma patients. This is demon-
strated by almost $1685/week higher productivity loss in
patients with a SCQ score of 15 in comparison to those with
a zero score. Productivity loss is a disregarded aspect of the
economic burden of asthma [16]. Thus this study is a
reminder for health care providers to pay greater attention
to comorbidities in the management of asthma in order to
reduce the burden of this common disease that dispropor-
tionately affects individuals in their productive years of life.
Appendix
Fig. 2 Incremental Costs of productivity loss based on comorbidity scores
Table 4 Costs of productivity loss per week (CAD)b, comparing
the main model with alternative model adding control status
as confounder
SCQ score Main Model Alternative modela
0 205.12 ± 42.09 215.05 ± 50.51
1 244.42 ± 45.46 253.10 ± 53.85
2 290.07 ± 51.73 296.62 ± 59.65
3 342.81 ± 62.54 346.31 ± 69.40
4 403.47 ± 79.29 402.74 ± 84.45
5 472.90 ± 103.02 466.56 ± 105.91
6 552.02 ± 134.70 538.45 ± 134.69
7 641.82 ± 175.39 619.12 ± 171.69
8 743.35 ± 226.39 709.36 ± 217.94
9 857.74 ± 289.24 809.96 ± 274.69
10 986.20 ± 365.75 921.82 ± 343.39
11 1130.04 ± 458.03 1045.86 ± 425.72
12 1290.72 ± 568.50 1183.12 ± 523.60
13 1469.79 ± 699.91 1334.70 ± 639.22
14 1669.0 ± 855.37 1501.83 ± 775.04*
15 1890.27 ± 1038.37* 1685.85 ± 933.81*
*P value is not significant
aAlternative model: two part model regression analysis on the main model
after adding control status
b2010 Canadian dollars
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